Positive phase 3 data reported for lenzilumab in hospitalised patients with COVID-19

Lenzilumab (a monoclonal antibody) improved the relative likelihood of survival without need for invasive mechanical ventilation (IMV) by 54% (n=520). Primary endpoint was ventilator-free survival measured through day 28 following treatment (HR:1.54; 95%CI:1.03-2.33, p=0.0365).

Biospace Inc.